In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1-negative tumors, progression-free survival was longer with the combination therapy ...
IpilimumabLung cancerMeta-analysisNivolumab and ipilimumab combination immunotherapy has become a standard treatment option for certain cancers. However, the benefits of combination therapy compared to nivolumab monotherapy in lung cancer patients are not entirely clear. We aimed to evaluate whether nivolumab...
Intestinal hypomotility as irAEs is exceedingly rare, and needs wider recognition given that the presentation is insidious. Here, we report a case of 79-year-old woman with metastatic melanoma under nivolumab and ipilimumab combination therapy. She developed ileus symptom, and was diagnosed with ...
A tailored approach utilizing the combination of nivolumab and ipilimumab as an immunotherapeutic boost following induction with single-agent nivolumab improved responses in the first and second line for patients with advanced renal cell carcinoma.
Neostar是报道的第一个以MPR为主要终点,在38%可切除非小细胞肺癌患者中测试单一新辅助剂nivolumab和nivolumab+ipilimumab的随机2期试验。尼伏卢单抗+ipilimumab产生的MPR率高于历史记录,联合治疗与尼伏卢单抗治疗相比存活率低得多。毒性情况总体上是可控的,没有新的安全问题。Nivolumab+ipilimumab可诱导CD3+和CD3+CD8+T淋...
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment in operable NSCLC remain unclear. We report the results of the phase 2 randomi
32 HNSCC patients are treated with 2 doses (in weeks 1 and 3) of immune checkpoint blockade (ICB) using nivolumab (NIVO MONO, n = 6, phase Ib arm A) or nivolumab plus a single dose of ipilimumab (COMBO, n = 26, 6 in phase Ib arm B, and 20 in phase IIa) prior to...
In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1–negative tumors, progression-free survival was longer with the combination therapy ...
19 Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cellsand immune tolerance. Cell 2008; 133: 775–87. 20 Kirn DH, Lynch TJ, Mentzer SJ, et al. Multimodality therapy ofpatients with stage IIIA, N2 non-small-cell lung cancer. Impact ofpreoperative chemotherapy on resectability and...
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133. doi:10.1056/NEJMoa1302369PubMedGoogle ScholarCrossref 26. Sznol M, Ferrucci PF, Hogg D, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with...